Navigation Links
Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
Date:7/2/2008

them for signs of anti-tumor activity. We look forward to sharing more data from this study as patient treatment and follow-up progress."

The primary objective of the multi-center Phase II clinical trial is to assess overall tumor response rate. Secondary objectives include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. All tumor responses in the trial are being evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Patients may continue to receive bavituximab as solo therapy after completion of chemotherapy as long as the cancer does not progress and side effects are acceptable. The trial is being conducted in the Republic of Georgia according to International Conference on Harmonization (ICH) and Good Clinical Practices (GCP) guidelines.

According to the RECIST criteria, patients are categorized as having "stable disease" ("SD") if they have less than a 20% increase to a 30% reduction in the sum of the target lesions, and they are categorized as having a "partial response" ("PR") if they experience greater than a 30% reduction in the sum of target lesions. In addition, to be assigned a status of SD or PR, patients cannot have the appearance of any new lesions.

According to the World Health Organization, breast cancer is the most commonly diagnosed cancer in women, and is second only to lung cancer as a leading cause of female cancer deaths. The National Cancer Institute estimates that approximately 182,460 U.S. women will be diagnosed with breast cancer in 2008 and 40,480 women will die of the disease in the U.S. alone.

Bavituximab is a monoclonal antibody that binds to the cellular membrane component phosphatidylserine (PS) that is usually located inside cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. By binding to PS, bavituximab is believed to h
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
2. Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
3. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
4. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
5. Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
6. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
7. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
8. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
9. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
10. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
11. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013  Sanofi (EURONEXT: SAN and NYSE: ... study, JAKARTA , examining the selective ... endpoint in both dose groups. The primary endpoint assessed ... volume. Consistent with data reported in previous trials, the ... vomiting. Full results will be presented at an upcoming ...
(Date:5/17/2013)... May 17, 2013  Boston Scientific Corporation (NYSE: ... annual EuroPCR Scientific Program May 21-24 in ... present a particularly rich and diversified set of data ... , M.D., global chief medical officer, Boston Scientific.  ... presented, including the NG PROMUS trial, which evaluated our ...
(Date:5/16/2013)...  PTC Therapeutics, Inc., today announced that it has ... U.S. Securities and Exchange Commission ("SEC") relating to the ... number of shares to be offered and the price ... (Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) J.P. ... managers for the offering. Cowen and Company is acting ...
Breaking Medicine Technology:Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2
... TRIANGLE PARK, N.C. , May 6 Chimerix, Inc., ... Thomas A. Pitler , Ph.D., has joined the company as Vice ... , , ... of experience, combining skills in business development and strategic planning with ...
... Intercell AG (VSE: ICLL) today announced that it has signed an agreement ... discovery. The technology is based on expression cloning of monoclonal antibodies from ... treat infectious diseases. , , ... the agreed terms Intercell will pay EUR 15 million to ...
Cached Medicine Technology:Chimerix Appoints Thomas Pitler, Ph.D., Vice President, Business Development 2Chimerix Appoints Thomas Pitler, Ph.D., Vice President, Business Development 3Intercell Acquires Antibody Technology Platform to Further Exploit Its Capabilities to Combat Infectious Diseases 2
(Date:5/19/2013)... Chicago, IL (PRWEB) May 19, 2013 In ... Surge, LLC, E-dentist.com has announced the launch of an SEO ... help dentists get high rankings in Google. , http://www.e-dentists.com/ ... do not pay for the service until they see results. ... sites. The lead generation websites run by JD Media Surge, ...
(Date:5/19/2013)... 19, 2013 According to a ... and Forecast (2013 – 2018): By Applications (Healthcare ... Technology (CCD, CMOS, Contact IS, Infrared, X-Ray) And ... sensor market was $8.00 billion in 2012 and ... at an estimated CAGR of 3.84% from 2013 ...
(Date:5/19/2013)... The Pradaxa lawyers at Bernstein Liebhard ... convened for hundreds of Pradaxa bleeding lawsuits ... U.S. District Court, Southern District of Illinois. According ... 14th, the Conference addressed the status of depositions and ... Conference that Defendants submitted a list of early trial ...
(Date:5/19/2013)... 2013 Vegas Hotel Escapes, the premier ... announce the launch it's all new vacation packages for ... on 5/19/2013. Consumers traveling to Las Vegas will be ... on VegasHotelEscapes.com's website. Travelers will be pleased to know ... price. , Vegas Hotel Escapes specializes in helping consumers ...
(Date:5/19/2013)... Rockford, IL (PRWEB) May 19, 2013 Beginning ... Rock River Valley Blood Center (RRVBC) will feature “Hot Dog ... and Belvidere. RRVBC will provide hot dogs and all ... feature ice-cold slushies each day throughout the summer. “Donors are ... to maintain a stable and adequate blood supply. This ...
Breaking Medicine News(10 mins):Health News:Effective New Dental SEO Solution Launched by E-dentists.com in Partnership with JD Media Surge, LLC 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 3Health News:Pradaxa Lawyers at Bernstein Liebhard LLP Report on Recent Status Conference in Federal Pradaxa Litigation 2Health News:Pradaxa Lawyers at Bernstein Liebhard LLP Report on Recent Status Conference in Federal Pradaxa Litigation 3Health News:Hot Dog Wednesdays and Ice Cold Slushies Return to Rock River Valley Blood Center for the Summer 2
... ... Two books provide a new way ... Literacy" is designed for teachers, and "HandMade Marks" is designed ... evaluation tools, hands-on exercises, and research questions, while also addressing ...
... ... UC-II®, is included in a new product from Nordic Naturals, the industry leader in ... 2010 Natural Products Expo West with great feedback from attendees looking for the latest, ... ...
... Those with abnormalities at initial screening often didn,t have ... News) -- Black Americans are less likely than whites ... on a flexible sigmoidoscopy screening test, says a new ... be at greater risk for colorectal cancer and more ...
... frequent returns to hospital for treatment, at higher rates than ... sickle cell disease often visit hospitals repeatedly in search of ... researchers found that one-third of sickle cell patients who visited ... relief. Young people, between the ages of 18 and 30, ...
... Mich.---The proportion of older middle-aged Americans who report disabilities ... in contrast to the disability decline that has been ... a new study by the RAND Corporation and the ... the proportion of Americans aged 50 to 64 who ...
... LOUIS -- In a broad-based review of studies focused on ... no evidence supporting the use of so-called "natural" treatments in ... wort, kava extract and valerian, herbal remedies touted on the ... anxiety wrote Kimberly Zoberi, M.D., associate professor of family and ...
Cached Medicine News:Health News:The Child's Way into Literacy: A New Look at Scribbling and Drawing 2Health News:InterHealth's UC-II in New Joint-Health Product from Nordic Naturals 2Health News:InterHealth's UC-II in New Joint-Health Product from Nordic Naturals 3Health News:InterHealth's UC-II in New Joint-Health Product from Nordic Naturals 4Health News:Blacks Less Likely to Get Follow-Up Colon Screening 2Health News:Sickle Cell Disease Patients Seek Acute Pain Care Repeatedly 2Health News:Sickle Cell Disease Patients Seek Acute Pain Care Repeatedly 3Health News:Middle-aged Americans report more mobility-related disabilities 2Health News:Middle-aged Americans report more mobility-related disabilities 3
... Respiratory Products, ,Westmed designs, manufacturers and ... and Respiratory professionals. Our mission is to ... clinician's ability to deliver quality medical care ... line. , ,Our web site is ...
... achieves optimum lung penetration for maximum therapeutic ... 1.04-1.10 µ at 6-8 LPM. Latex-free components. ... ,As the world leader in airway management ... of proven technology by offering top brands ...
... need for makeshift, modified nebulizer setups to ... gathering parts when your patient is critical? ... the utmost in Heliox rescue therapy. In ... becoming the standard of care in hospitals ...
... nebulizers offer a spill-proof design and effective ... 45° angle. All medical nebulizers are free-standing ... of configurations are available., ,All Portex® ... ,Portex® medication nebulizers feature consistently fine misting ...
Medicine Products: